We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment for Youth (Ages 8 to 16 Years Old) With Misophonia (U-HEAR) (U-HEAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04365543
Recruitment Status : Unknown
Verified April 2020 by Adam Lewin, University of South Florida.
Recruitment status was:  Recruiting
First Posted : April 28, 2020
Last Update Posted : April 28, 2020
Sponsor:
Collaborator:
University of Miami
Information provided by (Responsible Party):
Adam Lewin, University of South Florida

Brief Summary:
If someone is really sensitive to certain noises and sounds, they might have misophonia. U-HEAR is a study created to find out what helps kids and teens with misophonia. There are two treatments being tested in this study. The treatment your child receives will be determined at random. There will be a Two-Thirds (2/3rds or 66%) chance your child will receive a treatment called the Unified Protocol for Children and Adolescents (UP-C/A) that has been modified to meet the needs for youth with misophonia. There is a One-Third (1/3rd or 33%) chance your child will receive a treatment called Psychoeducation and Relaxation. All participants will get ten free treatment sessions. Each session will last one hour and happen once a week. The aim of the study is to evaluate the feasibility and preliminary efficacy of the UP-C/A for youth with misophonia.

Condition or disease Intervention/treatment Phase
Misophonia Behavioral: Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) for youth with misophonia Behavioral: Psychoeducation and Relaxation Therapy (PRT) Not Applicable

Detailed Description:
Misophonia is a condition characterized by intense affective and/or physical responses to auditory triggers. Negative affective states, including significant distress and avoidance are characteristic of misophonia. These negative emotional responses to trigger sounds, which result in behavioral problems and impairment, may be the primary targets for effective psychosocial intervention for misophonia. Transdiagnostic treatment approaches address clinically-significant distress through the use of evidence-based, cognitive-behavioral techniques (e.g., mindful awareness, problem-solving, and opposite action strategies) that allow for flexible and personalized treatment of core dysfunctions that cut across emotional disorders and lead to on-going impairment. This type of evidence-based, transdiagnostic approach includes skills applicable for problems observed frequently in misophonia including adaptability, problem solving, emotional (arousal) dysregulation and poor distress tolerance. The hypothesized mechanism of change of these core-dysfunction focused treatments is increased tolerance of distress in response to strong or intense emotion states. A secondary target is the reduction of maladaptive emotional behaviors (e.g., avoidance, aggression, escape) that may reinforce distress over time. To that end, this proposal aims to evaluate the feasibility and preliminary efficacy of the Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) for youth with misophonia. We will compare UP-C/A in a 2:1 ratio against a comparison condition (PRT: psychoeducation plus relaxation training), a behavioral approach that represents usual treatment in the community and has been utilized in clinical trials (35% response rate).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 124 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Unified Protocol to Help Emotions and Promote Auditory Relief (U-HEAR).
Actual Study Start Date : April 8, 2020
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: UP-C/A for Misophonia
The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) are manualized treatments for treating emotional disorders in youth. We have modified the UP-C/A to meet the needs for youth with misophonia.
Behavioral: Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) for youth with misophonia
Please see arm/group descriptions

Experimental: Psychoeducation and Relaxation Therapy
Psychoeducation and Relaxation Therapy (PRT) is a treatment that educates the child on misophonia and provides training in relaxation skills and tools for calming panic, anxiety and anger feelings.
Behavioral: Psychoeducation and Relaxation Therapy (PRT)
Please see arm/group descriptions




Primary Outcome Measures :
  1. Improvement in symptoms measured by Clinical Global Impression - Improvement (5 weeks) [ Time Frame: 5 weeks ]
    Clinical Global Impression-Improvement (CGI-I) is a 7-point clinician rated scale of treatment response anchored by 1 (very much improved) and 7 (very much worse). For categorical secondary outcomes, response is defined as a CGI-I rating of 1 or 2 (much improved/very much improved), and remission as CGI-S of 1 to 2. CGI-I will be used to measure symptom improvement after 5 weeks of treatment.

  2. Improvement in symptoms measured by Clinical Global Impression - Improvement (10 weeks) [ Time Frame: 10 weeks ]
    Clinical Global Impression-Improvement (CGI-I) is a 7-point clinician rated scale of treatment response anchored by 1 (very much improved) and 7 (very much worse). For categorical secondary outcomes, response is defined as a CGI-I rating of 1 or 2 (much improved/very much improved), and remission as CGI-S of 1 to 2. CGI-I will be used to measure symptom improvement after 10 weeks of treatment.

  3. Severity of symptoms measured by Clinical Global Impression - Severity (Baseline) [ Time Frame: Baseline ]
    Clinical Global Impression-Severity (CGI-S) is a widely used 7-point clinician rating of severity of psychopathology; raters will be instructed to score based on psychopathology and misophonia symptoms. Severity ratings range from 1 (no illness) to 7 (extremely severe). Severity will be measured before treatment begins to create a baseline for each participant.

  4. Severity of symptoms measured by Clinical Global Impression - Severity (5 weeks) [ Time Frame: 5 weeks ]
    Clinical Global Impression-Severity (CGI-S) is a widely used 7-point clinician rating of severity of psychopathology; raters will be instructed to score based on psychopathology and misophonia symptoms. Severity ratings range from 1 (no illness) to 7 (extremely severe). CGI-S will be used to measure severity after 5 weeks of treatment.

  5. Severity of symptoms measured by Clinical Global Impression - Severity (10 weeks) [ Time Frame: 5 weeks ]
    Clinical Global Impression-Severity (CGI-S) is a widely used 7-point clinician rating of severity of psychopathology; raters will be instructed to score based on psychopathology and misophonia symptoms. Severity ratings range from 1 (no illness) to 7 (extremely severe). CGI-S will be used to measure severity after 10 weeks of treatment.

  6. Overall impairment measured by Child's Global Assessment Scale (Baseline) [ Time Frame: Baseline ]
    Clinician rated measure of general functioning including impairment to capture functioning/impairment independent of diagnoses. The child or young person is given a single score between 1 and 100, based on a clinician's assessment of a range of aspects related to a child's psychological and social functioning. The score will put them in one of ten categories that range from 'extremely impaired' (1-10) to 'doing very well' (91-100. General functioning of the participant will be measured before treatment begins to create a baseline for each subject.

  7. Overall impairment measured by Child's Global Assessment Scale (5 weeks) [ Time Frame: 5 weeks ]
    Clinician rated measure of general functioning including impairment to capture functioning/impairment independent of diagnoses. The child or young person is given a single score between 1 and 100, based on a clinician's assessment of a range of aspects related to a child's psychological and social functioning. The score will put them in one of ten categories that range from 'extremely impaired' (1-10) to 'doing very well' (91-100). CGAS will be used to measure general functioning after 5 weeks of treatment.

  8. Overall impairment measured by Child's Global Assessment Scale (10 weeks) [ Time Frame: 10 weeks ]
    Clinician rated measure of general functioning including impairment to capture functioning/impairment independent of diagnoses. The child or young person is given a single score between 1 and 100, based on a clinician's assessment of a range of aspects related to a child's psychological and social functioning. The score will put them in one of ten categories that range from 'extremely impaired' (1-10) to 'doing very well' (91-100). CGAS will be used to measure general functioning after 10 weeks of treatment.


Secondary Outcome Measures :
  1. Misophonia symptoms as measured by Misophonia Assessment Questionnaire [ Time Frame: Baseline ]
    Misophonia Assessment Questionnaire (MAQ) is a 21 item, youth self-report, and parent-report questionnaire assessing severity and side effects of the youth's misophonia symptoms and reactions to misophonic sounds.

  2. Change in misophonia symptoms as measured by Misophonia Assessment Questionnaire [ Time Frame: 5 weeks ]
    Misophonia Assessment Questionnaire (MAQ) is a 21 item, youth self-report, and parent-report questionnaire assessing severity and side effects of the youth's misophonia symptoms and reactions to misophonic sounds.

  3. Change in misophonia symptoms as measured by Misophonia Assessment Questionnaire [ Time Frame: 10 weeks ]
    Misophonia Assessment Questionnaire (MAQ) is a 21 item, youth self-report, and parent-report questionnaire assessing severity and side effects of the youth's misophonia symptoms and reactions to misophonic sounds.

  4. Misophonia symptoms as measured by Misophonia Questionnaire [ Time Frame: Baseline ]
    The Misophonia Questionnaire is a 17-item questionnaire that assesses the presence of misophonia symptoms, emotions and behaviors associated with misophonic reactions, and symptom severity. The first two subscales are rated on a scale of 0 (not at all true) to 4 (always true). These two parts are summed to produce a total score ranging from 0 - 68. The severity subscale is a single item that asks an individual to provide a rating of their sound sensitivity on a scale from 0 (no sound sensitivities) to 15 (very severe sound sensitivities). The youth self-report (for those 10 and older) and parent report will serve as both a measure of symptoms of misophonia and allow for calculation of severity score.

  5. Change in misophonia symptoms as measured by Misophonia Questionnaire [ Time Frame: 5 weeks ]
    The Misophonia Questionnaire is a 17-item questionnaire that assesses the presence of misophonia symptoms, emotions and behaviors associated with misophonic reactions, and symptom severity. The first two subscales are rated on a scale of 0 (not at all true) to 4 (always true). These two parts are summed to produce a total score ranging from 0 - 68. The severity subscale is a single item that asks an individual to provide a rating of their sound sensitivity on a scale from 0 (no sound sensitivities) to 15 (very severe sound sensitivities). The youth self-report (for those 10 and older) and parent report will serve as both a measure of symptoms of misophonia and allow for calculation of severity score.

  6. Change in misophonia symptoms as measured by Misophonia Questionnaire [ Time Frame: 10 weeks ]
    The Misophonia Questionnaire is a 17-item questionnaire that assesses the presence of misophonia symptoms, emotions and behaviors associated with misophonic reactions, and symptom severity. The first two subscales are rated on a scale of 0 (not at all true) to 4 (always true). These two parts are summed to produce a total score ranging from 0 - 68. The severity subscale is a single item that asks an individual to provide a rating of their sound sensitivity on a scale from 0 (no sound sensitivities) to 15 (very severe sound sensitivities). The youth self-report (for those 10 and older) and parent report will serve as both a measure of symptoms of misophonia and allow for calculation of severity score.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The child meets criteria for misophonia
  • The child is currently living with their family/guardian(s)
  • The child is between 8 and 16 years old
  • Parent/legal guardian and child are able to read and speak English without a translator
  • Parent/legal guardian is able to attend weekly sessions and all assessments
  • If the child is on a psychotropic medication, they will need to be on a stable dose for 4 weeks prior to assessment (2 weeks for stimulant medication)

Exclusion Criteria:

  • The child has received prior UP-C/A treatment
  • The child is acutely suicidal
  • The child has a current diagnosis of psychosis, bipolar disorder, intellectual disability, alcohol/substance dependence, or eating disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04365543


Contacts
Layout table for location contacts
Contact: Kelly Kudryk, BA 813-586-1630 kellykudryk@miami.edu
Contact: Jane Mutch, PhD 727-767-8230 rothmanctr@usf.edu

Locations
Layout table for location information
United States, Florida
Child and Adolescent Mood and Anxiety Treatment (CAMAT) Program at the University of Miami Recruiting
Coral Gables, Florida, United States, 33124
Contact: Ashley Karlovich, BA    305-284-9852 ext 1    anxietylab@psy.miami.edu   
University of Florida Rothman Center Recruiting
Saint Petersburg, Florida, United States, 33701
Contact: Kelly Kudryk, BA    813-586-1630    kellykudryk@usf.edu   
Sponsors and Collaborators
University of South Florida
University of Miami
Investigators
Layout table for investigator information
Principal Investigator: Adam Lewin, PhD University of South Florida
Layout table for additonal information
Responsible Party: Adam Lewin, Associate Professor and Interim Division Chief, University of South Florida
ClinicalTrials.gov Identifier: NCT04365543    
Other Study ID Numbers: Pro#00042498
First Posted: April 28, 2020    Key Record Dates
Last Update Posted: April 28, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The sponsor requests de-identified data as a grant requirement in order to better the understand of misophonia. At the conclusion of the study, we will provide the de-identified data.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Approximately 2 years following the completion of the analyses. Duration of the availability is at Sponsor's discretion.
Access Criteria: Access is at Sponsor's discretion.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Adam Lewin, University of South Florida:
misophonia
sensory sensitivity
anxiety
sound